PMID: 9180866Jan 1, 1997Paper

Dose intensification of adjuvant chemotherapy in high-risk non-metastatic breast cancer: a critical review

Bulletin du cancer
G Ganem

Abstract

Dose intensification with or without hematopoietic support, tries to overcome resistance of breast cancer to conventional treatment. Rationale of this approach mainly is: (1) the existence of a dose response and/or a dose-intensity-effect relationships; (2) the selection of high-risk and chemosensitive patient population, with a low tumor burden at the time of dose intensification. Progress in supportive therapy has reduced the toxicity of dose intensification. The apparent benefit observed in pilot studies may be, in part, due to patient selection bias and definitive evaluation of the efficacy has to be addressed by prospective controlled trials. This article overviews rationale, main therapeutic results and future prospects with a critical viewpoint.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Jonathan A Ledermann
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Y NietoE F Shpall
Journal of Gastrointestinal Oncology
Salma K Jabbour, Charles R Thomas
© 2021 Meta ULC. All rights reserved